Elevance Health Inc

ELV is in a Stage 2 advance with a momentum breakout and lockout rally confirming new demand. Medium- and long-term biases are bullish, supported by rising EMAs and improving RSI and relative strength. Short-term execution is favorable now under lockout rally dynamics despite overbought signals. Best execution is to buy now on continuation above the breakout area or shallow pullbacks into the rising EMAs.

• ↑Dividend yield of 1.11% provides stable cash return.
• ↑High interest-rate sensitivity may boost earnings if rates drop.
• ↓Negative profitability factor highlights operational inefficiencies.